Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:592868.
doi: 10.1155/2014/592868. Epub 2014 Aug 4.

MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers

Tomohiro Fujiwara  1 , Toshiyuki Kunisada  2 , Ken Takeda  3 , Koji Uotani  4 , Aki Yoshida  4 , Takahiro Ochiya  5 , Toshifumi Ozaki  4
Affiliations
Review

MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers

Tomohiro Fujiwara et al. Biomed Res Int. 2014.

Abstract

Sarcomas are distinctly heterogeneous tumors and a variety of subtypes have been described. Although several diagnostic explorations in the past three decades, such as identification of chromosomal translocation, have greatly improved the diagnosis of soft tissue sarcomas, the unsolved issues, including the limited useful biomarkers, remain. Emerging reports on miRNAs in soft tissue sarcomas have provided clues to solving these problems. Evidence of circulating miRNAs in patients with soft tissue sarcomas and healthy individuals has been accumulated and is accelerating their potential to develop into clinical applications. Moreover, miRNAs that function as novel prognostic factors have been identified, thereby facilitating their use in miRNA-targeted therapy. In this review, we provide an overview of the current knowledge on miRNA deregulation in soft tissue sarcomas, and discuss their potential as novel biomarkers and therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Examples of clinical applications of miRNAs as biomarkers and therapeutics for patients with soft tissue sarcoma. As therapeutics: ① combination with neoadjuvant chemotherapy, ② combination with adjuvant chemotherapy, and ③ combination with chemotherapy for metastasis. As biomarkers: ❶ diagnosis, ❷ determination of drug resistance, ❸ monitoring after treatment for primary lesions, ❹ detection for micrometastasis, and ❺ monitoring after treatment for metastasis. ADR: adriamycin; IFO: ifosfamide; GEM: gemcitabine; DOC: docetaxel.
See this image and copyright information in PMC

References

    1. Misra A, Mistry N, Grimer R, Peart F. The management of soft tissue sarcoma. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2009;62(2):161–174. - PubMed
    1. Toro JR, Travis LB, Hongyu JW, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. International Journal of Cancer. 2006;119(12):2922–2930. - PubMed
    1. Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss's Soft Tissue Tumors. 5th edition. Mosby Elsevier; 2008.
    1. Fujiwara T, Kawai A, Yoshida A, Ozaki T, Ochiya T. Cancer Stem Cells of Sarcoma. New Hampshire, UK: CRC Press; 2013.
    1. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. Journal of Clinical Oncology. 2002;20(16):3470–3477. - PubMed

Publication types

LinkOut - more resources